NanoDx has signed a licensing agreement with IBM Research to use the latter’s metal-oxide semi-conductive (CMOS) compatible nanoscale sensors to boost and extend precise, rapid testing for various indications.
The companies intend to develop tests for Covid-19, traumatic brain injury (TBI), sepsis and stroke.
At present, NanoDx is seeking an emergency use authorisation from the US Food and Drug Administration for a quick Covid-19 test, which can deliver results in two minutes at point-of-care.
NanoDx president and CEO Sharad Joshi said: “This global pandemic has further highlighted the need for a convenient, fast and accurate diagnostic so proper treatments can be delivered to patients as quickly as possible with the goal of shortening recovery times.
“As we move forward, our access to IBM’s technology in the in vitro diagnostics and biosensor fields will enable us to pursue developing a high throughput diagnostics platform at a significantly lower cost.”
NanoDx is currently marketing a real-time, point-of-care diagnostics platform called NanoDx System, which can identify and measure biomarkers or analytes using a minimal fluid sample in under two minutes.
Furthermore, the company has set up a broad intellectual property portfolio based on its nanosensor design and production processes that integrate the complete in vitro diagnostics field.
IBM Research hybrid Cloud research vice-president Mukesh Khare said: “Notably, this CMOS-compatible device can be manufactured in an existing foundry, providing easily scalable and cost-effective hardware.
“The integration of this technology design with NanoDx’s highly advanced nanosensor platform can help accelerate the ability to bring an extensive array of diagnostic solutions to market.”
Meanwhile, NanoDx has collaborated with the Home Base Program to boost awareness of the long-term issues linked to TBI in both active and retired military personnel.